Author

Stefan Schreiber

TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS
TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Stefan Schreiber  et al.

TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION
TO THE SOURCES OF INFLAMMATORY BOWEL DISEASE: PRE-HISTORIC INTRODUCTION OF IL-23 RECEPTOR RELATED GENETIC SUSCEPTIBILITY TO INFLAMMATION INTO TODAY'S EUROPEAN POPULATION

Stefan Schreiber  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Stefan Schreiber  et al.

COMPARISON OF REAL-WORLD TREATMENT PERSISTENCE AND SAFETY OF VEDOLIZUMAB AND ANTI-TUMOR NECROSIS FACTOR-ALPHA TREATMENT IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
COMPARISON OF REAL-WORLD TREATMENT PERSISTENCE AND SAFETY OF VEDOLIZUMAB AND ANTI-TUMOR NECROSIS FACTOR-ALPHA TREATMENT IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN’S DISEASE: SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

Stefan Schreiber  et al.

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

Stefan Schreiber  et al.

EARLY RESTORATION OF TRYPTOPHAN DEGRADATION IS ASSOCIATED WITH THERAPY RESPONSE IN ULCERATIVE COLITIS AND DEPENDS ON JAK-STAT SIGNALING
EARLY RESTORATION OF TRYPTOPHAN DEGRADATION IS ASSOCIATED WITH THERAPY RESPONSE IN ULCERATIVE COLITIS AND DEPENDS ON JAK-STAT SIGNALING

Stefan Schreiber  et al.

THE INTERPLAY OF ATG16L1 AND XBP-1 CRUCIALLY COORDINATES EPITHELIAL DNA DAMAGE RESPONSES AND PROTECTS FROM INTESTINAL CARCINOGENESIS
THE INTERPLAY OF ATG16L1 AND XBP-1 CRUCIALLY COORDINATES EPITHELIAL DNA DAMAGE RESPONSES AND PROTECTS FROM INTESTINAL CARCINOGENESIS

Stefan Schreiber  et al.

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY

Stefan Schreiber  et al.

INDUCTION AND MAINTAINANCE OF STEROID-FREE REMISSION OVER 52 WEEKS WITH VEDOLIZUMAB IN A CASE WITH STEROID-REFRACTORY TYPE 2 AUTOIMMUNE PANCREATITIS
INDUCTION AND MAINTAINANCE OF STEROID-FREE REMISSION OVER 52 WEEKS WITH VEDOLIZUMAB IN A CASE WITH STEROID-REFRACTORY TYPE 2 AUTOIMMUNE PANCREATITIS

Stefan Schreiber  et al.

THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE AND REMISSION WAS ASSOCIATED WITH BETTER QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS
THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE AND REMISSION WAS ASSOCIATED WITH BETTER QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS

Stefan Schreiber  et al.

ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION
ETRASIMOD IMPROVES QUALITY OF LIFE IN ADULTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 OASIS TRIAL AND OPEN-LABEL EXTENSION

Stefan Schreiber  et al.

MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN
MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: IMPROVEMENT IN INFLAMMATORY BOWEL DISEASE SCORES IN PARTICIPANTS OF THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAIN

Stefan Schreiber  et al.

RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT OR BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN IBDQ SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Stefan Schreiber  et al.

THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE OR REMISSION WAS ASSOCIATED WITH BETTER WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS
THE ADDITION OF BOWEL URGENCY IMPROVEMENT TO THE ACHIEVEMENT OF CLINICAL RESPONSE OR REMISSION WAS ASSOCIATED WITH BETTER WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS FROM MIRIKIZUMAB PHASE 3 TRIALS

Stefan Schreiber  et al.

INTESTINAL ULTRASOUND IN MONITORING POSTOPERATIVE CROHN´S DISEASE
INTESTINAL ULTRASOUND IN MONITORING POSTOPERATIVE CROHN´S DISEASE

Stefan Schreiber  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Stefan Schreiber  et al.

RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN WPAI SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITI
RELATIVE ASSOCIATION OF BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND BOWEL URGENCY REMISSION VS STOOL FREQUENCY REMISSION AND RECTAL BLEEDING REMISSION WITH IMPROVEMENT IN WPAI SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITI

Stefan Schreiber  et al.

MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES
MIRIKIZUMAB IMPROVES WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE SCORES IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: THE LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Stefan Schreiber  et al.

IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION
IMPACT OF FILGOTINIB ON INDIVIDUAL INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE ITEMS: POST HOC ANALYSES FROM SELECTION

Stefan Schreiber  et al.

EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH
EARLY MOLECULAR SIGNATURES OF THERAPEUTIC RESPONSE TO VEDOLIZUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE PATIENTS IDENTIFIED USING A LONGITUDINAL MULTI-OMICS APPROACH

Stefan Schreiber  et al.

Item 41 - 60 / 86
1 2
3
4 5